TARRYTOWN, N.Y., June 11, 2020 /PRNewswire/ —
Clinical program consists of four separate study populations: two for treatment and two for prevention
First studies evaluate safety and efficacy in hospitalized and non-hospitalized patients with COVID-19
Two-antibody ‘cocktail’ is designed to help protect against viral escape
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initiation of the first clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19. The REGN-COV2 clinical program will consist of four separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure (such as healthcare workers or first responders) and uninfected people with close exposure to a COVID-19 patient (such as the patient’s housemate). The placebo-controlled trials will be conducted at multiple sites.
“We have created a unique…